AMENDMENTS TO THE CLAIMS

List of claims:

1. (Original) An immunocomplex for raising an immune response in an individual against an antigenf said immunocomplex comprising the antigen and Fas ligand (FasL) as an adjuvant.

2. (Original) An immunocomplex according to claim 1 wherein the immune response is a CD4 immune response.

3. (Original) An immunocomplex according to claim 1 wherein the antigen is a tumour associated antigen.

4. (Original) A immunocomplex according to claim 1 wherein the antigen is a bacterial or viral antigen

5. (Currently Amended) An immunocomplex according to ~~any one of the preceding claims~~ claim 1 wherein said immunocomplex is a fusion protein of the antigen and FasL.

6. (Currently Amended) An immunocomplex according to ~~any one of claims 1 to 3~~ claim 1 wherein said immunocomplex is a tumour cell expressing FasL.

7.(Original) An immunocomplex according to claim 6 wherein the tumour cell is a melanoma cell.

8. (Currently Amended) An immunocomplex according ~~to any one of the preceding claims~~ claim 1 further comprising an agent capable of complementing the FasL adjuvant.

9. (Original) An immunocomplex according to claim 8 wherein the agent is capable of depleting CD25 expressing cells in vivo.

10. (Currently Amended) An immunocomplex according to claim 8 wherein the agent is an anti-CD25 monoclonal antibody.

11. (Original) A nucleic acid molecule encoding an immunocomplex according to claim 5.

12. (Currently Amended) A pharmaceutical composition comprising an immunocomplex ~~or a nucleic acid according to any one of the preceding claims~~. Claim 1.

13. (Original) A method of providing an immunocomplex comprising a tumour associated antigen and FasL, said method comprising transfecting a tumour cell with FasL such that the ligand is expressed by the transfected cell along with the tumour associated antigens.

14. (Original) A method of providing an immunocomplex comprising a pathogen associated antigen and FasL, said method comprising transfecting or transform ng a pathogen cell w th FasL such that the ligand is expressed by the transfected cell along with the pathogen associated antigens.

15. (Cancelled) ~~Use of an immunocomplex according to any one of claims 1 to 10, or a nucleic acid molecule according to claim 11, or an immunocomplex as produced by the method of claim 13 or claim 14, in the preparation of a medicament for inducing an immune response in an individual against an antigen, wherein said medicament is administered to an individual so as to induce an antibody immune response against said antigen.~~

16. (Currently amended) A method of inducing an immune response in an individual against an antigen, comprising the step of administering to said individual an immunocomplex <u>according to claim 1</u>.~~any one of claims 1 to 10, an immunocomplex as~~

~~produced by the method of claim 13 or claim 14, a nucleic acid according to claim 11, or a pharmaceutical composition according to claim 12.~~

17. (Original) A method of providing an immunocomplex for inducing an immune response in an individual against a tumour cell, said method comprising obtaining a tumour cell from said individual; and transfecting said cell with FasL such that said cell expresses FasL.

18. (Canceled~~) Use of a transfected tumour cell produced by a method according to claim 17 in the preparation of a medicament for inducing an antibody immune response in said individual against said tumour.~~

19. (Original) A method of treating cancer in an affected individual, comprising the step of administering a transfected tumour cell produced by a method according to claim 17.

20. (Original) A method of identifying cell-specific antibodies comprising (a) transfecting a cell with FasL; (b) vaccinating a test animal with said transfected cell; (c) collecting serum from said test animal; and (d) identifying antibodies specific for said cell from the serum.

21. (Original)A method according to claim 20 further comprising the step (e) producing monoclonal antibodies from said identified antibodies.

22. (Currently Amended) A method according to claim 20 ~~claim 20 or claim 21~~ further comprising the step of producing a pharmaceutical composition comprising said antibodies.

23. (Currently Amended) A method of identifying specific cell associated antigens comprising (a) contacting an antibody identified by a method according to claim 20 ~~claim 20 or claim 21~~ with a plurality of potential cell associated antigens; (b) identifying specific binding between said antibody and an antigen; and (c) characterising said antigen.

24. (Currently amended) A method according to claim 23 wherein said potential cell associated antigens are derived from the cell used to identify the tumour specific antibodies ~~according to claim 20 or claim 21~~.

25. (Currently amended) A method according to claim 23 ~~claim 23 or claim 24~~ wherein the potential cell associated antigens are displayed using an expression library or fixed to a solid support.

26. (Currently amended) A method according to claim 23 ~~any one of claims 23 to 25~~ wherein the specific binding between said antibody and an antigen is identified by a labelling technique.

27. (Currently amended) A method according to claim 20 ~~any one of claims 20 to 26~~, wherein said cell is a tumour cell, and said cell associated antigens are tumour associated antigens.

28. (New) A method of inducing an immune response in an individual against an antigen, comprising the step of administering to said individual an immunocomplex as produced by the method of claim 13.

29. (New) A method of inducing an immune response in an individual against an antigen, comprising the step of administering to said individual a nucleic acid according to claim 11.

30. (New) A method of inducing an immune response in an individual against an antigen, comprising the step of administering to said individual pharmaceutical composition according to claim 12.

31. (New) A pharmaceutical composition comprising a nucleic acid according to claim 11.

32. (New) A method of inducing an immune response in an individual against an antigen, comprising the step of administering to said individual pharmaceutical composition according to claim 31.